drug
discoveri
cn
disord
restrict
inabl
therapeut
agent
cross
bloodbrain
barrier
bbb
moreov
current
drug
aim
correct
neuron
cell
signal
therebi
neglect
pathophysiolog
chang
affect
cell
type
neurovascular
unit
nvu
compon
nvu
pericyt
microglia
astrocyt
neuron
basal
lamina
act
intric
network
maintain
neuron
homeostat
microenviron
consequ
disrupt
intric
cell
network
lead
neuron
malfunct
symptom
characterist
cn
diseas
lack
understand
nvu
signal
cascad
may
explain
current
treatment
cn
diseas
cur
current
therapi
treat
symptom
maintain
neuron
function
refocus
drug
discoveri
sustain
nvu
function
may
provid
better
method
treatment
promot
neuron
surviv
review
examin
current
therapeut
common
cn
diseas
describ
import
nvu
cerebr
homeostasi
discuss
new
possibl
drug
target
technolog
aim
improv
treatment
drug
deliveri
diseas
brain
moreov
patient
afflict
complex
cn
diseas
typic
requir
lifelong
medic
margin
improv
qualiti
life
therapeut
neurosurg
approach
improv
outcom
neurolog
disord
ie
hydrocephalu
benign
tumor
epilepsi
certain
cn
diseas
amyotroph
later
sclerosi
al
multipl
sclerosi
ms
predominantli
unrespons
current
treatment
explan
lack
effect
therapi
current
drug
aim
improv
neuron
function
fail
address
underli
diseas
patholog
given
disappoint
recent
neuroprotect
agent
futur
studi
must
emphas
import
transport
across
blood
brain
barrier
bbb
consid
use
drug
neuroprotect
regen
properti
achiev
long
last
effect
function
outcom
savitz
schabitz
estim
small
molecul
drug
larg
molecul
drug
market
enter
brain
achiev
concentr
need
therapeut
benefit
pardridg
pharmacokinet
properti
eg
protein
bind
rapid
clearanc
metabol
contribut
limit
drug
bioavail
peripheri
howev
bbb
metabol
physic
barrier
restrict
passag
molecul
peripher
circul
cerebr
circul
difficulti
develop
drug
cross
bbb
illustr
studi
character
market
medic
drug
capabl
enter
brain
ghose
viswanadhan
wendoloski
chemic
properti
favor
passag
across
bbb
brain
includ
lipophil
natur
size
larger
da
affin
endogen
transport
system
ie
transport
protein
receptormedi
absorpt
transcytosi
pardridg
heterogen
natur
variabl
brain
region
vascular
contribut
complex
face
cn
drug
deliveri
must
explor
cn
drug
current
develop
cross
bbb
due
size
polar
lack
endogen
transport
pathway
pardridg
current
research
elucid
limit
cross
bbb
therefor
cn
drug
develop
concentr
small
lipophil
chemic
structur
moieti
possess
endogen
transport
system
degener
dopaminerg
neuron
substantia
nigra
par
compacta
snpc
classifi
movement
disord
parkinson
diseas
pd
first
line
therapi
moder
sever
pd
includ
combin
therapi
ldopa
larginin
carbidopa
acid
provid
symptomat
relief
increas
central
dopamin
level
ldopa
metabol
precursor
dopamin
cross
bbb
via
larg
neutral
amino
acid
transport
undergo
decarboxyl
dopamin
brain
sinc
peripher
dopamin
enter
brain
adjuv
therapi
carbidopa
peripher
dopa
decarboxylas
inhibitor
necessari
increas
ldopa
bioavail
prevent
dopamin
convers
peripheri
two
medic
supplement
neuron
function
provid
precursor
neurotransmitt
dopamin
howev
efflux
pump
limit
bioavail
oral
dose
less
enter
brain
hawkin
mokashi
simpson
longterm
ldopacarbidopa
treatment
lead
drug
toler
reemerg
symptom
vaamond
flore
weisser
ibanez
obeso
medic
maintain
neuron
function
short
time
ultim
select
dopaminerg
neuron
degener
snpc
ensu
neuropatholog
chang
alzheim
diseas
ad
character
presenc
cortic
atrophi
neurofibrillari
tangl
neurit
plaqu
bell
zlokov
howev
undefin
role
neuroanatom
chang
ad
progress
consensu
exist
causal
silvestrelli
et
al
alter
behavior
cognit
ad
associ
loss
cholinerg
input
bartu
consequ
patholog
chang
brain
anatomi
much
like
pd
treatment
current
ad
therapi
aim
replac
deplet
level
neurotransmitt
treat
symptom
donepezil
acetylcholinesteras
inhibitor
improv
cognit
patient
mild
moder
ad
brousseau
et
al
enhanc
acetylcholin
bioavail
donepezil
cross
bbb
organ
cation
transport
kim
et
al
howev
pglycoprotein
pgp
mediat
efflux
limit
therapeut
concentr
donepezil
acetylcholinesteras
inhibitor
brain
ishiwata
threshold
treatment
patient
toler
low
dose
therapi
secondari
advers
peripher
side
effect
increas
cholinerg
activ
ad
progress
beyond
moder
stage
patient
unrespons
therapi
number
neuron
neuron
synaps
limit
scheff
et
al
huntington
diseas
autosom
domin
neurodegen
diseas
affect
movement
cognit
glutamin
repeat
extens
huntingtin
gene
well
document
associ
hd
yet
huntingtin
protein
function
remain
unknown
treat
hd
particularli
challeng
due
lack
understand
diseas
etiolog
gap
knowledg
limit
current
treatment
option
focus
symptomat
relief
depress
psychosi
chorea
involuntari
writh
movement
chorea
difficult
symptom
treat
recent
manag
tetrabenazin
tbz
antipsychot
medic
fasano
et
al
frank
et
al
tbz
promot
neurotransmitt
degrad
prevent
reuptak
monoamin
neurotransmitt
presynapt
vesicl
ondo
hanna
jankov
even
though
tbz
one
drug
avail
treat
chorea
fewer
side
effect
analog
drug
reserpin
kenney
neuronfocus
medic
halt
diseas
progress
epilepsi
character
spontan
recurr
seiz
episod
due
uncontrol
repetit
neuron
fire
antiepilept
drug
a
provid
symptomat
relief
modifi
neurotransmiss
three
differ
mechan
increas
gabaerg
inhibitori
activ
decreas
glutaminerg
excitatori
activ
modifi
ion
conduct
patient
longer
respond
a
treatment
diseas
state
categor
refractori
epilepsi
treatment
option
patient
refractori
epilepsi
invas
procedur
vagal
nerv
stimul
murphi
hemispherectomi
obrador
larramendi
chandra
et
al
complet
remov
affect
area
resect
penfield
baldwin
schramm
clusmann
studi
shown
refractori
epilepsi
coincid
increas
express
pglyprotein
multidrug
resist
efflux
pump
may
limit
therapeut
concentr
a
enter
brain
tishler
et
al
lazarowski
et
al
patholog
refractori
epilepsi
better
understood
invas
procedur
remain
treatment
option
malign
glioma
common
brain
tumor
worst
prognosi
treat
brain
cancer
particularli
challeng
chemotherapi
drug
eg
carboplatin
methorex
leucovorin
cyclophosphamid
etc
limit
bbb
permeabl
bart
et
al
intraarteri
deliveri
chemotox
drug
use
temporari
osmot
open
bbb
increas
drug
deliveri
tumor
osmot
open
bbb
increas
drug
deliveri
tumor
kroll
et
al
howev
disrupt
bbb
use
invas
procedur
associ
transient
neurolog
deficit
increas
risk
seizur
haluska
anthoni
focus
ultrasound
less
invas
mechan
revers
barrier
open
promot
local
drug
deliveri
method
show
promis
control
dose
deliveri
affect
brain
region
howev
like
osmot
open
preclin
studi
indic
posttreat
damag
indic
ubiquin
neuron
alonso
et
al
reorgan
tight
junction
protein
alonso
et
al
deposit
astrocyt
neuron
gap
junction
plaqu
alonso
et
al
ultrasound
barrier
open
may
offer
better
prognosi
liu
et
al
patient
malign
cnsrelat
cancer
treatment
studi
need
assess
risk
perman
brain
damag
age
effect
vascular
function
basal
level
inflamm
rosen
et
al
perski
wassertheilsmol
leav
age
nvu
vulner
insult
advanc
age
primari
risk
factor
stroke
neurodegen
diseas
pd
ad
etc
factor
ignor
anim
model
studi
diseas
ignor
age
preclin
studi
may
account
larg
fail
neuroprotect
clinic
trial
stroke
neurodegen
diseas
koziol
feng
lohl
reichmann
howev
recent
clinicallyrelev
age
anim
model
stroke
develop
sahakyan
et
al
baccarelli
et
al
specif
stroke
wellestablish
risk
factor
eg
age
diabet
hypertens
dyslipidemia
etc
correl
increas
circul
inflammatori
mediat
inflammatori
peripher
marker
may
play
role
cerebrovascular
diseas
tuttolomondo
et
al
thu
mediat
stroke
occurr
wellsubstanti
associ
specif
peripher
mediat
biomark
stroke
risk
occurr
yet
exist
identifi
understand
function
peripher
inflammatori
mediat
bbb
give
insight
better
clinic
diagnosi
stroke
moreov
innov
neuroprotect
may
emerg
better
understand
heterogen
natur
stroke
patholog
brain
region
variabl
eg
vascular
blood
flow
type
neuron
prolong
neuroinflamm
etc
nvu
compon
ie
bbb
astrocyt
pericyt
microglia
neuron
work
togeth
coordin
fashion
maintain
homeostat
neuron
microenviro
figur
pardridg
regul
intracellular
signal
cascasd
key
compon
maintain
metabol
homeostasi
neuron
dysregul
intracellular
signal
network
may
initi
step
lead
nvu
patholog
neuron
dysfunct
figur
intracellular
signal
cell
type
alter
passag
substanc
brain
modifi
bbb
receptor
express
bbb
function
integr
abbott
mani
cn
diseas
decreas
bbb
function
integr
preced
neuron
damag
dinapoli
et
al
abraham
et
al
lee
et
al
kermod
et
al
katz
et
al
ujii
dickstein
carlow
jefferi
thu
indic
role
nvu
dysfunct
bbb
dysfunct
current
drug
develop
effort
often
look
contribut
nonneuron
cell
develop
progress
diseas
state
pathophysiolog
signal
cascad
nvu
cell
must
better
understood
target
therapi
develop
restor
neuron
microenviron
cerebr
endothelium
possess
metabol
physic
barrier
limit
molecular
passag
brain
figur
endotheli
enzym
eg
xanthin
oxidas
mao
metabol
molecul
may
decreas
bioactiv
cn
drug
efflux
pump
eg
pgp
mdr
mrp
etc
ablumin
surfac
extrud
molecul
back
peripher
circul
ad
wijesuriya
et
al
epilepsi
lunatorto
et
al
express
efflux
pump
may
contribut
unrespons
drug
therapi
efflux
pump
inhibit
rigor
et
al
may
provid
new
mechanist
target
improv
drug
deliveri
pharmacoresist
diseas
state
physic
characterist
bbb
differ
peripher
capillari
bed
due
absenc
fenestr
presenc
tight
junction
occlud
zonula
occulden
jam
junction
limit
pincytot
transport
close
apposit
astrocyt
neuron
microglia
tight
junction
provid
physic
electr
barrier
restrict
molecular
passag
alter
express
tight
junction
protein
decreas
function
integr
characterist
pathophysiolog
chang
bbb
cn
diseas
chang
implic
diseas
includ
ad
bowman
et
al
pd
curran
becker
al
zhong
et
al
epilepsi
marchi
et
al
restor
bbb
integr
may
provid
method
save
exist
neuron
retain
homeostat
microenviron
small
molecul
signal
cascad
alter
neuron
microenviron
induc
function
chang
bbb
permeabl
diseas
onset
bbb
function
integr
may
worsen
time
allow
passag
molecul
normal
restrict
cerebr
circul
huber
et
al
brain
studi
shown
bbb
integr
induc
experiment
transform
growth
bfgf
gdnf
stimul
abbott
likewis
region
differ
vascular
vascular
permeabl
may
allow
passag
target
therapi
would
typic
exclud
brain
therapi
design
restor
maintain
intact
bbb
may
prolong
onset
cn
diseas
eg
bbb
permeabl
prece
ad
diagnosi
starr
et
al
pericyt
send
cellular
project
penetr
basal
lamina
ensheath
approxim
microvessel
circumfer
doreduffi
lamanna
close
interact
support
idea
pericyt
commun
endotheli
cell
pericyt
gap
junction
cell
adhes
contact
allt
lawrenson
cn
pericyt
lack
contractil
protein
alpha
actin
unlik
perhipher
pericyt
howev
evid
suggest
cn
pericyt
help
regul
cerebr
blood
flow
krueger
bechmann
propos
role
pericyt
brain
includ
maintain
bbb
integr
angiogenesi
matur
endotheli
cell
bbb
phenotyp
dohgu
et
al
kutcher
herman
exampl
cocultur
primari
rat
brain
pericyt
cerebr
endotheli
cell
induc
tight
junction
format
convers
inhibit
pericytesecret
lead
reduc
tight
junction
format
bbb
integr
hellstrom
et
al
factor
eg
pdgf
fgf
epo
mmp
releas
brain
pericyt
may
contribut
microvasculatur
membran
remodel
observ
peripheri
huang
et
al
consequ
lack
pericyt
deriv
factor
may
contribut
patholog
chang
brain
detach
pericyt
vasculatur
pericyt
apoptosi
ie
pericyt
ghost
observ
diabet
retinopathi
lead
patholog
chang
aberr
vasculogenesi
endotheli
hyperplasia
mccarti
brain
proteoglycan
essenti
contact
adhes
protein
stabil
pericytesendothelium
interact
retina
brain
pathway
may
potenti
drug
target
decreas
vasculogenisi
kimelberg
tumor
help
maintain
capillari
function
incid
stroke
small
vessel
diseas
nagelhu
et
al
astrocyt
special
glia
cell
regul
metabol
factor
eg
glucos
neurotransmitt
ion
blood
flow
etc
affect
neuron
function
neuhau
end
feet
envelop
brain
microvasculatur
gap
adheren
junction
astrocyt
end
feet
provid
mode
intercellular
commun
endothelium
aquaporin
primari
water
channel
locat
end
feet
contribut
endotheli
cell
polar
brain
water
volum
wolburg
et
al
astrocyt
secret
factor
induc
bbb
phenotyp
endotheli
cell
cultur
croitorulamouri
et
al
didier
et
al
vegf
fibroblast
growth
promot
angiogenesi
regul
bbb
transport
benarroch
physiolog
state
pathophysiolog
state
astrocyt
respond
inflamm
trauma
cacheaux
et
al
releas
proinflammatori
cytokin
dauchi
et
al
alter
bbb
chemokin
receptor
express
song
wang
patholog
chang
due
neuroinflamm
may
featur
astrocyt
novel
drug
target
astrocyt
dysfunct
lay
key
role
epilepsi
point
alter
potassium
glutam
homeostasi
chakraborti
et
al
enhanc
tgfb
signal
gao
ji
enhanc
local
drug
metabol
garden
moller
likewis
evid
activ
astrocyt
characterist
patholog
chang
brain
diseas
psychiatr
disord
like
depress
qian
flood
hong
neurodegen
diseas
like
hd
pd
lee
landreth
neuropath
pain
persidski
patholog
role
astrocyt
cn
diseas
emerg
may
soon
lead
astrocytetarget
therapi
microglia
stem
monocyt
lineag
gener
innat
adapt
immun
respons
within
cn
brain
expos
injuri
ischemia
inflammatori
stimuli
microglia
undergo
morpholog
chang
stellat
ramifi
activ
confirm
physic
chang
permit
microglia
initi
inflammatori
respons
within
brain
cell
prolifer
move
site
injuri
engulf
cell
debri
lai
process
neuroprotect
role
activ
inflammatori
cascad
lead
neurodegener
excess
ro
releas
astrocyt
prevail
theori
field
neurodegen
diseas
research
point
neuroinflamm
sourc
complic
potenti
area
treatment
haskin
et
al
martinpadura
et
al
basement
membran
structur
made
heterogen
protein
matrix
compos
actin
laminin
integrin
collagen
fibronectin
proteoglycan
protein
layer
separ
brain
capillari
nearbi
nvu
cell
provid
support
cell
attach
migrat
data
suggest
basal
lamina
also
play
role
intercellular
commun
regul
cell
adhes
molecul
martinpadura
et
al
actin
organ
influenc
tight
junction
rearrang
may
contribut
enhanc
bbb
permeabl
fournier
et
al
tight
junction
protein
interconnect
transmembran
cytosol
portion
basal
lamina
zonula
occluden
belong
membraneassoci
guanyl
kinas
famili
thu
indic
role
signal
transduct
fournier
et
al
junction
adhes
molecul
jam
belong
immunoglobin
superfamili
promot
leukocyt
transmigr
endotheli
adhes
molecul
express
hyong
et
al
drug
design
stabil
basal
lamina
interact
may
protect
bbb
permeabl
chang
subsequ
neuroinflamm
current
therapi
aim
correct
neuron
function
limit
success
treat
cn
diseas
manag
symptom
medic
earli
stage
diseas
effect
yet
diseas
progress
often
lead
use
higher
dose
medic
unwant
side
effect
medic
may
longer
help
symptom
manag
flow
chart
depict
nvu
dysfunct
clinic
diagnosi
view
figur
target
nvu
primarili
focus
upon
vasculatur
success
treat
limit
cn
diseas
progress
egleton
et
al
gynther
et
al
howev
propos
drug
target
ineffect
without
drug
transport
across
bbb
remaind
review
discuss
advanc
strategi
drug
deliveri
cn
prodrug
defin
therapeut
inact
agent
enzymat
convert
activ
metabolit
prodrug
enhanc
bioavail
drug
metabol
occur
brain
peripheri
bbb
possess
enzym
mayb
use
prodrug
convers
prodrug
well
character
better
understood
mechan
involv
circul
molecul
enter
cn
interact
endogen
transport
protein
capillari
endothelium
carrier
mediat
transport
cmt
facilit
passag
molecul
essenti
brain
metabol
util
cmt
passag
enhanc
cn
drug
deliveri
ldopa
drug
conjug
gynther
et
al
ldopa
prodrug
use
transport
enter
brain
brain
ldopa
convert
dopamin
activ
compound
one
studi
demonstr
endogen
transport
watersolubl
nsaid
ketoprofen
across
bbb
conjug
ltyrosin
substrat
begley
situ
brain
perfus
confirm
ketoprofenltyrosin
hybrid
enter
brain
use
concentrationdepend
manner
result
studi
novel
pharmacokinet
drug
complex
brain
parenchyma
remain
unclear
target
endogen
transport
protein
ideal
drug
deliveri
method
limit
modifi
chemic
compound
favor
passag
brain
may
result
loss
drug
function
bioactiv
may
alter
drug
convert
activ
form
current
usag
pd
ad
show
efficaci
diseas
treatment
may
best
use
conjunct
treatment
stabil
nvu
function
molecular
trojan
hors
permit
noninvas
deliveri
larg
molecul
brain
use
rmt
bell
zlokov
larger
molecular
weight
peptid
insulin
transferrin
leptin
transport
across
bbb
receptor
mediat
transcytosi
rmt
peptidomimet
monoclon
antibodi
mab
follow
path
enter
brain
receptor
specif
mab
bind
exofaci
epitop
bbb
differ
endogen
ligand
order
interfer
endogen
ligand
transport
pardridg
insulin
trasferrin
system
use
mab
research
proof
concept
shown
conjug
peptid
bdnf
tfr
pardridg
howev
insulin
receptor
compar
better
candid
rmt
drug
deliveri
human
insulin
mab
himab
activ
time
effect
human
tfr
boado
et
al
ulbrich
et
al
success
preclin
trial
use
himab
includ
transport
neuroprotect
peptid
like
bdnf
may
therapeut
benefit
diseas
like
stroke
marini
et
al
memori
disord
longo
et
al
depress
yulug
et
al
reintroduc
essenti
enzym
like
tyrosin
hydroxylas
pd
zhang
et
al
decoy
receptor
reduc
neuroinflamm
zhang
et
al
antibodi
fibril
ferri
brain
boado
et
al
latter
novel
find
show
possibl
bidirect
drug
transport
across
bbb
primari
concern
deliveri
larger
molecul
drug
accumul
brain
endotheli
astrocyt
efflux
pump
may
limit
abil
extrud
larger
molecul
brain
parchemya
pardridg
liposom
selfsustain
bilay
phospholipid
sphingolipid
form
small
unilaminar
multilamellar
vesicl
witt
et
al
use
drug
deliveri
lipid
sphere
nontox
biocompati
deliv
lipophil
hydrophil
amphoter
drug
either
within
sphere
sphere
surfac
liposom
enhanc
drug
bioavail
protect
thereapeut
agent
metabol
bodi
therebi
prolong
drug
pharmacokinet
profil
circulatori
system
moreov
immunolabel
liposom
potenti
sitespecif
deliveri
novel
brain
target
technolog
like
mab
trojan
hors
cdna
sirna
treat
sever
cn
diseas
instanc
cancer
enclos
drug
within
liposom
increas
probabl
extravas
tumor
vasculatur
alam
et
al
specif
liposom
modifi
surfac
target
affect
tissu
organ
illustr
cancer
rheumatoid
arthriti
treatment
goren
et
al
treatment
cancer
multilamellar
vesicl
doxorubicin
effect
doxorubicin
administ
alon
william
et
al
specif
doxorubicin
tumor
therapi
studi
use
oblig
anaerob
protein
target
hypox
region
tumor
lead
enhanc
local
releas
tumor
papahadjopoulo
et
al
use
conjug
liposom
show
promis
target
cancer
poor
prognosi
like
glioma
cheong
et
al
advanc
liposom
nanoshel
contain
nanos
vesicl
permit
continu
releas
drug
differ
standard
liposom
undergo
one
ruptur
event
arai
et
al
technolog
use
treatment
neoplast
mening
acut
lymphoma
fewer
less
sever
side
effect
observ
compar
standard
treatment
sancho
et
al
fewer
number
side
effect
may
attribut
slower
drug
releas
improv
sitespecif
deliveri
liposom
technolog
potenti
improv
pharmacodynam
properti
current
cn
drug
therapi
promot
better
treatment
lower
dose
eg
neuropsychiatr
drug
chronic
pain
medic
cholinerg
stimul
drug
ad
addit
potenti
exist
enhanc
site
specif
drug
deliveri
gene
therapi
describ
option
avail
replac
dysfunct
gene
work
copi
howev
use
viral
vector
reintroduc
cdna
function
gene
use
sirna
silenc
mutant
gene
show
promis
clinic
purpos
method
extens
use
vitro
studi
understand
protein
function
show
potenti
translat
clinic
therapi
lack
essenti
protein
lead
neuron
degener
malign
glioma
insert
cdna
hiv
adeno
herep
viru
common
method
deliv
gene
cell
vector
util
cell
replic
machineri
mrna
transcript
protein
translat
retrovirus
one
first
recombin
vector
use
clinic
set
phase
ii
clinic
studi
recurr
malign
glioma
show
favor
safeti
profil
benesch
et
al
yet
due
immunogen
safeti
concern
adeno
herp
retro
viru
vector
consid
limit
clinic
use
silenc
gene
express
use
sirna
may
therapeut
benefit
reduc
mutant
protein
hd
ad
ion
channel
neurotransmittor
transcript
factor
growth
factor
growth
receptor
categori
potenti
therapeut
target
furthermor
sirna
show
promis
revers
patholog
vivo
diseas
model
ad
hd
al
neuropath
pain
anxieti
depress
etc
addit
immunogen
concern
viral
vector
deliveri
shortcom
sirna
includ
decreas
potenc
due
rna
instabl
variabl
transfect
efficaci
poor
intracellular
uptak
high
probabl
offtarget
effect
lead
decreas
gene
express
gene
decreas
express
intend
gene
drouet
et
al
deliveri
system
involv
viral
vector
initi
cytotox
prakash
et
al
immunolog
complic
davi
et
al
within
cn
nonvir
nake
cdna
sirna
may
limit
immunorel
complic
use
transfect
reagent
immunolabel
liposom
deliv
nake
cdna
sirna
may
reduc
complic
instabl
offtarget
deliveri
enhanc
bioactiv
potenti
less
frequent
lower
dose
bbb
respond
peripher
central
factor
serv
signal
interfac
cn
peripheri
li
et
al
sever
diseas
eg
hypertens
diabet
etc
associ
increas
circul
inflammatori
mediat
bank
montecucco
pend
quercioli
mach
alter
vascular
immun
function
marsland
et
al
vivo
studi
pinpoint
abil
peripher
mediat
influenc
bbb
inflammatori
mediat
secret
li
et
al
puddu
et
al
thu
surpris
peripher
inflamm
influenc
bbb
structur
function
gosselin
rivest
brook
et
al
astrocyt
signal
brook
et
al
exampl
circul
upregul
comorbid
diseas
state
ronaldson
et
al
lewi
jr
et
al
key
player
microglia
astrocyt
inflammatori
respons
peripher
level
may
affect
patholog
neuroinflamm
howev
effect
specif
cytokin
neuroimmunomodul
well
defin
concept
modul
inflammatori
mediat
prevent
vascular
event
novel
eg
heart
attack
stroke
etc
barr
et
al
studi
examin
level
circul
inflammatori
factor
eg
found
posit
correl
specif
inflammatori
mediat
bbb
disrupt
castillo
et
al
morbid
worsen
stroke
outcom
patient
gelosa
et
al
mccoll
et
al
likewis
reduc
peripher
inflamm
lead
better
experiment
stroke
outcom
schondorf
et
al
experiment
elev
prestrok
peripher
inflamm
lead
worsen
poststrok
damag
coincid
chang
tight
junction
rearrang
schondorf
et
al
prevent
treatment
reduc
peripher
inflamm
may
ideal
target
prestrok
prevent
adjuv
therapi
poststrok
treatment
treatment
approach
may
efficaci
prevent
vascularassoci
dementia
latelif
cognit
impair
increas
risk
ad
patient
diabet
understand
nvu
dysfunct
lead
novel
drug
target
aim
supplement
neuron
function
provid
symptomat
relief
role
astrocyt
microglia
pericyt
bbb
emerg
cn
patholog
thu
emphas
need
drug
design
sole
focus
neuron
equal
import
need
understand
bbb
dynam
interact
cn
peripheri
evid
suggest
peripher
mediat
influenc
barrier
function
time
peripher
inflamm
may
alter
neuroinflammatori
pathway
one
problem
cn
drug
develop
physic
metabol
restrict
bbb
select
permit
molecular
passag
peripher
cerebr
circul
howev
trojanhors
prodrug
method
employ
endogen
transport
system
ie
cmt
rmt
carri
therapeut
brain
show
promis
clinic
use
current
liposom
improv
outcom
patient
cancer
increas
drug
bioavil
reduc
therapeut
dosag
furthermor
immunolabel
liposom
abil
advanc
site
specif
drug
deliveri
make
gene
therapi
feasibl
shield
cdna
sirna
peripher
degrad
better
insight
cn
diseas
patholog
improv
drug
deliveri
cn
effect
therapi
horizon
astrocyt
interpret
neuron
signal
modifi
releas
factor
order
help
maintain
neuron
metabol
need
astrocyt
end
feet
close
contact
cerebr
endothelium
help
regul
blood
flow
tight
junction
integr
b
tight
junction
uniqu
phenotyp
cerebr
capillari
distinctli
differ
peripher
capillari
tight
junction
provid
epitheliallik
qualiti
bbb
creat
physic
electr
barrier
prevent
paracellular
molecular
passag
c
pericyt
maintain
basal
lamina
depict
structur
may
regul
blood
flow
evid
suggest
basal
lamina
point
contact
nvu
intracellular
commun
proper
structur
need
send
respond
cellcel
commun
microglia
cerebr
monocyt
possess
stellat
shape
physiolog
condit
physiolog
function
microglia
within
nvu
well
defin
figur
pathophysiolog
nvu
cell
interact
neuron
distress
signal
best
character
inflammatori
cytokin
distress
signal
releas
neuron
alter
nvu
function
astrocyt
interpret
distress
signal
becom
activ
releas
inflammatori
cytokin
cascad
may
activ
nearbi
astrocyt
depend
degre
inflamm
b
signal
releas
asctrocyt
end
feet
lead
decreas
tight
junction
integr
signal
may
result
enzym
releas
eg
lead
tight
junction
protein
degrad
lack
tight
junction
protein
form
factor
combin
c
pericyt
ghost
character
cn
commonli
describ
peripher
capillari
dysfunct
dysfunct
lack
pericyt
lead
basal
lamina
thicken
dysregul
nvu
cell
signal
hemodynam
cerebr
blood
flow
microglia
respond
inflammatori
signal
result
mobil
ramifi
shape
cerebr
macrophag
phagocyt
debri
releas
cytotox
factor
propag
neuroinflamm
releas
inflammatori
cytokin
balanc
stellat
ramifi
state
essenti
maintain
cerebr
homeostasi
metabol
physic
barrier
schemat
adjac
cerebr
endotheli
cell
bbb
possess
physic
metabol
mechan
discret
microenviron
form
within
brain
support
optim
neuron
function
efflux
pump
mdr
mrp
pgp
present
ablumin
surfac
activ
extrud
molecul
endotheli
cell
therebi
prevent
passag
brain
b
metabol
enzym
mao
present
ablumin
surfac
andor
within
endotheli
cell
protein
degrad
harm
molecul
metabol
potenti
drug
therapi
therebi
prevent
drug
activ
c
tight
junction
celltocel
contact
consist
transmembran
protein
eg
junction
adhes
molecul
occludin
claudin
tight
junction
creat
physic
barrier
limit
paracellular
passag
electr
barrier
repel
molecul
attempt
bbb
transport
cn
diseas
state
progress
schemat
depict
relationship
nvu
dysfunct
cn
diseas
progress
understand
patholog
nvu
signal
give
incit
potenti
drug
target
inwhich
maintain
neuron
microenviron
neuron
function
